>
产品中心 >
Functional_antibody >
Neuromics/IGF-I R/CD221-Fluorescein Labeled/FC15010/100 Tests
Type:MouseIgG
Applications:FC
E=ELISA;FACS;FC=FlowCytometry;FPLC=FastProteinLiquidChromatography;GF=GravityFlow;HPLC=HighPerformanceLiquidChromatography;ICC=Immunocytochemistry;IF=Immunofluorescence;IHC=Immunohistochemistry;IP=Immunoprecipitation;NAC=Non-adherentCellAssays;NB=NeutralizationofBioactivity;SE=SandwichELISA;TPE=TargetedProteinExpression;WB=Westernblotting;;AC=AdherentCellAssays;FM=FluorescentMicsroscopy;;;BSC-CM5=BiacoreSensorChipCM5;BSM=BiosactiveSmallMoleculeorPeptide;CDM=CellDifferentiationMedia;;;;;;HealthandFitness;;;DNAExtraction/Purification;;InvivoLikeAssaysSpeciesReactivity:H;R
B=Bovine;Ca=Cat;Ch=Chicken;D=Dog;EQ=Equine;GP=GuineaPig;H=Human;M=Mouse;P=Porcine;Pr=Primate;R=Rat;Rb=Rabbit;Y=Yeast;Xe=Xenopus;Ze=Zebrafish;;;;NA-NotApplicable;STP=Step-TactinProteins;AllFormat:ProteinGPurified-liquid
Immunogen:Clone#:33255
Insulin-likeGrowthFactorstypeIandIIaresmallproteinsstructurallyrelatedtoinsulinthathavebothgrowthpromotinganddifferentiationactivityonavarietyofcells(1).TheiractionismediatedthroughbindingoftheIGF-Ireceptor(IGF-IR).IGF-IRisatetramerconsistingoftwoextracellular125kDaαchainsand2transmembrane95kDaβchains(2).IGF-IRhastyrosinekinaseactivtity,whichislinkedtotheras-raf-MAPKsignalingpathway.IGF-IandIGF-IIbindIGF-IRwithaKsofapproximately1-10nM(3).TwootherreceptorshavealsobeenreportedtobindIGFs:insulinreceptorandIGF-IIR.AnumberofIGFbindingproteinspresentinplasmaareinvolvedinIGFtransportandtheyappeartoalsoregulatetheinteractionofIGFswiththeirreceptorsbycontrollingtheamountoffreeIGFsavailableforreceptorinteractions(4).IGF-IRshavebeenimplicatedinpromotingtumorgrowththroughtheiranti-apoptoticaction.FurThermore,IGF-IRmayassociatewithcollagen-bindingintegrinstoregulatecelladhesion(5).ThesepropertiesmakethemonitoringofIGF-IRoncellsurfacesanimportantexerciseinunderstandingmalignantcelltransformationandtumorprogression.
MAB391isamonoclonaldirectedtotheextracellulardomainoftheIGF-IR.ThismonoclonalhasalsobeenshowntoneutralizeIGFactivityonthehumanMCFbreastepithelialtumorcellline.
References:
1.Ornitz,D.M.andN.Itoh(2001)GenomeBiol.2:3005.1
2.Powers,C.J.etal.(2000)Endocrin.Relat.Cancer7:165.
3.Keegan,K.etal.(1991)Proc.Natl.Acad.Sci.USA88:1095.
4.Johnson,D.E.andL.T.Williams(1993)Adv.CancerRes.60:1.
5.Murgue,B.etal.(1994)CancerRes.54:5206.
1.Rotwein,P.(1991)GrowthFactors5:3.
2.LeRoith,D.etal.(1993)Ann.NewYorkAcad.Sci.692:22.
3.Rosenfeld,R.G.etal.(1987)Bioechem.Biophys.Res.Comm.143:199.
4.Bach,L.A.etal.(1993)J.Biol.Chem.268:9246.
5.Shakibaei,M.etal.(1999)Biochem.J.342:615.
